EUCTR2009-015870-36-SE进行中（未招募）不适用
icotine pharmacodynamics with a new oral nicotine replacement product and NiQuitin Lozenge. A study in healthy smokers.
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- McNeil AB
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Healthy male or female subjects between the ages of 19 and 55 years, inclusive. Health is defined as the absence of clinically relevant abnormalities as identified by a detailed medical history, a physical examination, and blood pressure, pulse rate and hemoglobin measurements, as judged by the investigator or an authorized physician. The responsible physician may order additional investigations or analyses if necessary.
- •2.Smoking within 30 minutes of waking up.
- •3.Smoking of at least 10 cigarettes daily during at least one year preceding inclusion.
- •4.For females: Postmenopausal state (absence of menstrual discharge for at least two years and a serum FSH level exceeding 30 IU/L) or premenopausal/perimenopausal state with an effective means of contraception (oral, injected or implanted hormonal contraceptives, intrauterine device, or status after operative sterilization), or declared absence of sexual contact during the study.
- •5.Body Mass Index (BMI) between 17.5 and 32.0 kg/m2 and a total body weight >= 50.0 kg.
- •6. A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
- •7.Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Evidence or history of an acute or chronic medical or psychiatric condition or allergy or laboratory abnormality, or of use of drugs that, in the judgment of the investigator or an authorized study physician, increases the risk associated with study participation or interfere with the interpretability of study results.
- •2.Females: Pregnancy, breast-feeding, premenopausal, or perimenopausal, state with insufficient contraception as specified under Inclusion Criteria.
- •3.History of regular alcohol consumption in the 6 months before screening, exceeding weekly limits of 2 L of wine or 5 L of beer or 0.6 L of spirits for females, and 3 L of wine or 7.5 L of beer or 0.9 L of spirits for males. The investigator may lower these limits if a subject consumes different types of alcoholic beverages.
- •4.Use of other NRT, bupropion, or varenicline, or history of a quit attempt later than 3 months before the screening visit.
- •5.Treatment with an investigational product, other than those described in this protocol, between 1 month preceding the first treatment visit and the last treatment visit of the study.
- •6.Pathological oral status interfering with normal muscular, sensory, or absorptive function of the oral cavity.
- •7.Prior regular use of nicotine mouthspray and/or nicotine lozenge.
- •8.Relationship to persons involved directly with the conduct of the study (i.e,, principal investigator; subinvestigators; study coordinators; other study personnel; employees or contractors of the sponsor or Johnson & Johnson subsidiaries; and the family of each).
研究者
相似试验
进行中（未招募）
不适用
ICOTINE PHARMACODYNAMICS WITH A NEW ORAL NICOTINE REPLACEMENT PRODUCT AND NICOTINE GUM 4 MG. A STUDY IN HEALTHY SMOKERS.Tobacco DependenceEUCTR2010-023268-42-SEMcNeil AB
已完成
1 期
Pharmacokinetics of orally-administered Nicotinamide Powder 10% Zonne and its NAD+ pathway metabolitesot applicableJPRN-UMIN000031610Hamamatsu University School of Medicine8
已完成
不适用
Pharmacokinetics With a New Oral Nicotine Replacement Product and Nicorette® GumTobacco DependenceNCT01152736McNeil AB19
进行中（未招募）
1 期
Effects of Nicotine 1.5mg lozenge on smoking urges in moderate smokersCTIS2023-506787-13-00Pierre Fabre Medicament180
已完成
1 期
Clinical evaluation of the new nicotinic receptor marker (-)- [18F]NCFHEB with Positron Emission Tomography in Alzheimer’s disease patients, and healthy volunteersG30Alzheimer diseaseDRKS00000472niversität Leipzig49